Mice infected with high doses of Mycobacterium bovis BCG (3 x 107) showed a marked impairment of delayed-type hypersensitivity to PPD in vivo, and their splenic T cells failed to proliferate when cultured in vitro with concanavalin A or PPD. However, this state of unresponsiveness could be reversed both in vitro and in vivo by the administration of an interleukin 2 (IL-2)-containing preparation. IL-2 produced spontaneously by the gibbon lymphosarcoma T-cell line MLA-144 and T-cell-conditioned medium from a mixed lymphocyte reaction were able to increase DNA synthesis of splenic T lymphocytes from BCG-immunosuppressed mice cultured with concanavalin A or PPD. Furthermore, BCG-infected mice treated in vivo with at least 100 U of IL-2 showed a positive skin reaction to PPD, and their spleen cells were fully responsive in vitro. The reversal of BCG-induced immunosuppression was not observed when infected mice were injected with IL-2 preparations previously incubated with blast cells, a procedure known to remove IL-2 activity. These results indicate that the basis of BCG-induced unresponsiveness is a deficiency in the production of IL-2 rather than a lack of reactive T cells.
Several reports have demonstrated that high doses of Mycobacterium bovis BCG, injected intravenously (i.v.) in mice, rats, and guinea pigs, cause T-cell unresponsiveness (8, 16) . Similarly, military tuberculosis and disseminated lepromatous disease in humans are associated with loss of delayed-type hypersensitivity (DTH) skin reactions (2, 3) . Both in humans and in experimental animals, this unresponsiveness is, at least in part, due to the presence of suppressor cells (9, 20, 22, 23) . I have recently reported that, in mice, BCG-induced T suppressor cells inhibit DNA synthesis in vitro by releasing a nonspecific suppressive factor which blocks the production of interleukin 2 (IL-2) (5) . From this observation arises the question of whether IL-2 can reverse specific and nonspecific loss of cell-mediated immunity in BCG-infected mice.
In the last 2 years, several pieces of evidence have indicated that IL-2 administration either in vitro or in vivo influences T-cell reactivity such as the development of alloreactive cytotoxic T cells (14, 24) , tumor-specific T cells (4) , transplantation tolerance (18a), and antigen-induced Tcell proliferation (15) . This paper investigates the effect of IL-2 administration of BCG-induced T-cell unresponsiveness and shows that specific DTH skin reactions and T-cell proliferation to concanavalin A (ConA) and PPD are markedly increased by treatment with IL-2-containing preparations. Rabin et al. (21) . The second source of IL-2 was provided by culturing 106 CBA spleen cells with 106 BALB/c cells per ml of medium (RPMI 1640) in a classical mixed lymphocyte reaction (MLR). Both MLA-144-and MLR-conditioned media were concentrated by ultrafiltration through a Diaflo UM2 membrane (Amicon Corp., Lexington, Mass.). In a portion of these two T-cell-conditioned media, the IL-2 activity was removed by absorption on ConA-induced blast cells (12) . Bovine serum albumin was added (1 mg/ml) to both preparations, and they were extensively dialyzed against phosphate buffer solution and finally filtered ( (8, 9) . I have recently reported that this inhibition of T-cell reactivity is due, at least in part, to a lack of IL-2 production (5). This experiment was undertaken to test whether the addition of exogenous IL-2 preparation in the culture reverses in failure of T cells to react to ConA and PPD.
MATERIALS AND METHODS

Infection
Two T-ceil-conditioned media containing IL-2 were used. One consisted of a 24-h culture supernatant from MLA-144 cells, a gibbon line producing spontaneously high levels of IL-2 (21). The second was a 72-h culture supernatant from CBA anti-BALB/c MLR. Both of these conditioned media supported the growth of an IL-2-dependent cytotoxic T-cell line (CTLL) (Fig. 1) . The dose-response curve shows that a 3% dilution increased the DNA synthesis of CTLL, indicating a clear presence of IL-2 activity. Figure 1 also shows that IL-2 activity can be removed by absorbing active supernatants on ConA-induced blast cells.
T-cell-enriched populations from BCG-infected animals failed to respond in vitro to conA and PPD (Fig. 2) . However, when 25% of IL-2-containing supernatant from MLA-144 or MLR was added to the culture, a strong proliferative response to conA and PPD was observed. This effect is clearly due to IL-2 present in the conditioned medium, as supernatants absorbed on blast cells failed to produce such effects. Also, the antigen priming of the animal is required, as PPD-stimulated cultures of uninfected mice did not show any proliferative response to IL-2.
T-cell-conditioned media containing IL-2 reverse in vivo the impairment of DTH to PPD in BCG-infected mice. In this experiment I tested the ability of IL-2 to reverse the impairment of DTH to PPD observed in BCG-infected mice (i.v.). (Fig. 3A) . IL-2 (100 U) was also able to increase PPD reactivity when injected daily from days 8 to 12 or from days 12 to 16 (Fig.  3B) . In contrast, no effect was observed when an IL-2 preparation was injected before BCG infection or in the first 4 days. Figure 4 repeats the basic observation using either MLA-144 or MLR IL-2 preparations and also shows that the same preparations devoid of IL-2 by absorption on blast cells failed to reverse the inhibition of DTH to PPD. This IL-2-mediated reversal of DTH inhibition is total if compared to the DTH response of mice infected with BCG intradermally in the footpad.
T cells from mice infected with BCG and treated with IL-2 preparations are fully responsive in vitro to conA and PPD. The following experiment was undertaken to test whether IL-2 administration in vivo reverses the failure of T cells from BCG-infected mice to proliferate in vitro. For this purpose, mice were injected with 100 U of MLA-144 or MLR IL-2 preparations from days 4 to 8 of BCG infection. Three days after the last injection of IL-2, nylon-enriched T cells were put into a culture and stimulated with either conA or PPD. Cells from mice infected i.v. failed to proliferate when compared with cells from mice infected in the footpad (Fig.  5) . However, both IL-2 preparations gave rise to T cells able to proliferate in vitro, whereas mice treated with absorbed conditioned media contained cells which failed to respond to conA and PPD. DISCUSSION It is known that i.v. infection with high doses of BCG causes cell-mediated unresponsiveness evident in vitro as inhibition of specific and nonspecific proliferative response and in vivo an impairment of DTH footpad reaction to PPD (8, 16, 20, 22) . In contrast, mice infected intradermally with BCG are fully responsive. Several mechanisms responsible for such immunosuppression have been suggested (3, 7, 16) , including suppressor cell activation (9, 20, 23) . The observation that two IL-2 preparations are able to fully reverse in vitro the BCG-induced inhibition of T-cell proliferation stimulates interest in the possible use of IL-2 in vivo. For this purpose, the same IL-2 preparations were injected intraperitoneally into BCG-infected mice. Both IL-2 preparations supported the development of DTH reactivity to PPD and the proliferative response to conA and PPD. In contrast, T-cell-conditioned media from which IL-2 was removed by absorption on blast cell failed to do so.
It has been recently reported that systemic administration of IL-2 in vivo increases T-cell reactivity in nude and normal mice (14, 24) . However, the fate of IL-2 after intraperitoneal or i.v. injection has been shown to be very short (10) . This can explain, at least in part, the requirement of high levels of IL-2 activity in the injected T-cell-conditioned medium (100 U) and the failure of this effect when an IL-2 preparation was injected before or in the first 4 days of infection. It is interesting to note that in BCG-unresponsive mice T cells are able to respond to PPD in vitro from days 4 to 8 when T suppressor cells are not operative (9) .
Together, the in vitro and in vivo results reported in this paper suggest that the proliferative T-cell defect and the failure of DTH reactivity to PPD are not due to the absence of or a generalized lack of triggering of immune T cells but may be related to a deficiency in events leading to IL-2 production. This possibility has been suggested by previous work showing that BCG-activated T suppressor cells release a nonspecific inhibitor of IL-2 production responsible, at least in part, for the observed unresponsiveness (5). Furthermore, a lack of IL-2 production has been repoited in several systems to be responsible for T-cell unresponsiveness. Unresponsiveness to contact sensitizing agents such as oxazolone and picryl chloride is mediated by a complex T suppressor cell circuit which influences IL-2 production (1, 17, 18 ).
T-cell unresponsiveness in lepromatous leprosy is reversed in vitro by the addition of T-cell-conditioned medium ( (11) and in patients suffering from acquired immune deficiency syndrome (19) : preliminary results have suggested that IL-2 is able to produce a remarkable reconstitution of T-cell activity.
The next question that I would like to answer in the model of BCG-induced unresponsiveness is whether IL-2 administration in vivo supports the development of reactive T cells despite the presence of T suppressor cells or whether exogenous IL-2 blocks the production of suppressor cells.
